EVA1C, also known as eva-1 homolog C, is a gene with multiple functions. It is a novel Slit receptor, and its expression pattern is consistent with an axon guidance role in the mouse nervous system, playing a part in the formation of neural circuitry [3]. It may also be involved in the Wnt signaling pathway, as a switch from noncanonical to canonical Wnt signaling activates EVA1C to inhibit neuroblast migration [4].

In terms of disease-related findings, in WHO grade II/III glioma, high EVA1C expression is associated with malignant clinicopathological features and poor overall survival, and it is positively associated with immune infiltration levels of multiple immune cells, suggesting it could be a potential prognostic biomarker and a predictor of high immune infiltration [1]. In neonatal hypoxic-ischemic encephalopathy (NHIE), the expression of EVA1C is upregulated in relevant cell models. Silencing EVA1C can increase cell survival and growth, potentially associated with alternative splicing, indicating its potential as a therapeutic target for NHIE [2].

In conclusion, EVA1C has important functions in neural development and may play a role in multiple disease conditions. Studies on EVA1C contribute to our understanding of neural circuit formation, glioma prognosis, and the mechanism of NHIE, providing potential directions for disease diagnosis, prognosis prediction, and treatment.